Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue		$ 182,784	$ 286,151	$ 477,727	$ 541,392
Cost of goods sold		85,261	118,390	177,918	192,106
Gross margin		97,523	167,761	299,809	349,286
General and administrative expense		3,211,817	3,310,368	6,040,293	4,808,314
Operations expense		521,116	1,271,258	1,069,869	1,737,824
Sales and marketing expense		133,015	685,029	397,424	1,239,245
Total operating loss		(3,768,425)	(5,098,894)	(7,207,777)	(7,436,097)
Gain on revaluation of cash advances to Helomics			1,222,244		1,222,244
Other income		(52,965)	3,223	(52,968)	(50,209)
Other expense		(729,837)	(607,343)	(1,846,912)	(1,157,711)
Gain (loss) on derivative instruments		422,081	211,940	394,974	231,348
Gain on notes receivables associated with asset purchase		1,290,000		1,290,000
Loss on equity method investment					(439,637)
Gain on revaluation of equity method in investment			6,164,260		6,164,260
Net income (loss)		(3,577,378)	1,465,104	(8,106,695)	(1,828,080)
Deemed dividend on Series E Convertible Preferred Stock			20,398		20,398
Net income (loss) attributable to common shareholders per common shares-basic and diluted		$ (3,577,378)	$ 1,444,706	$ (8,106,695)	$ (1,848,478)
Gain (loss) per common share basic (in dollars per share)		$ (0.36)	$ 0.49	$ (1.10)	$ (0.81)
Gain (loss) per common share diluted (in dollars per share)		$ (0.36)	$ 0.24	$ (1.10)	$ (0.81)
Weighted average shared used in computation - basic (in shares)	[1]	9,838,152	2,960,937	7,362,240	2,274,754
Weighted average shared used in computation - diluted (in shares)		9,838,152	6,007,078	7,362,240	2,274,754

[1] Includes 1,390,166 contingently issuable shares related to prefunded warrants when outstanding during the six months ended June 30, 2020 and 122,000 abeyance shares during the six months ended June 30, 2020.